Genzyme acquired Bioenvision thus expanding its product portfolio in the field of cancer, autoimmune diseases and infections. The deal gains Genzyme marketed products including Evoltra®/Clolar® (clofarabine) and Modrenal® (trilostane). The deal would worth up to US$345 M to Bioenvision.